Glimital-M1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glimital-M1 Forte effective in achieving optimal blood glucose levels when diet and exercise alone are insufficient. The prolonged-release formulation ensures a steady plasma concentration, reducing the frequency of dosing and minimizing gastrointestinal side effects commonly associated with metformin. Glimital-M1 Forte is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in elderly patients and those with cardiovascular disease. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. This combination therapy should be used under medical supervision to optimize efficacy and safety in glycemic management.